Dr. Ip on the Utility of Carboplatin, Pemetrexed, and Pembrolizumab in Lung Adenocarcinoma
In Partnership With:
Andrew Ip, MD, discusses carboplatin, pemetrexed, and pembrolizumab as first-line therapy in recurrent/metastatic non–small cell lung cancer.
Andrew Ip, MD, Hematologic Oncology, John Theurer Cancer Center, Hackensack University Medical Center, discusses carboplatin (Paraplatin), pemetrexed (Alimta), and pembrolizumab (Keytruda) as first-line therapy in recurrent/metastatic non–small cell lung cancer.
In an ongoing analysis, investigators studied 523 patients treated at Hackensack University Medical Center and Memorial Sloan Kettering Cancer Center to determine outcomes with carboplatin, pemetrexed, and pembrolizumab, Ip says. At the time of analysis, the median overall survival for patients was 11 months, Ip adds. However, this is a stark contrast to what was expected based on a previous report of a 17-month overall survival benefit with the triplet, Ip concludes.
